A GLP-1R agonist
货号:ajcx23464
CAS:N/A
分子式:C187H291N45O59.XC2H4O2
分子量：4113.6
溶解度:DMF: 30 mg/ml,DMSO: 30 mg/ml,DMSO:PBS (pH 7.2) (1:4): 0.2 mg/ml
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Semaglutide is an agonist of glucagon-like peptide 1 receptor (GLP-1R; EC₅₀= 6.2 pM in a reporter assay using BHK cells expressing the human receptor).¹It decreases blood glucose levels in thedb/dbmouse model of type 2 diabetes (ED₅₀=<2 nmolkg). semaglutide (25 kg)prevents decreases in the number of dopaminergic neurons substantia nigra and increases lipid peroxidation striatum, as well improves motor coordination rotarod footprint tests a mouse model parkinson's disease induced by mptp.²It decreases neuronal loss in the hippocampal dentate gyrus and CA1 and CA3 regions and improves motor coordination and grip strength in the beam-walking and hanging wire tests, respectively, in a rat model of stroke induced by permanent middle cerebral artery occlusion (MCAO) when administered at a dose of 10 nmol/kg every other day.³Formulations containing semaglutide have been used in the treatment of type 2 diabetes.

1.Lau, J., Bloch, P., SchÄffer, L., et al.Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutideJ. Med. Chem.58(18)7370-7380(2015) 2.Zhang, L., Zhang, L., Li, L., et al.Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse modelNeuropeptides7170-80(2018) 3.Yang, X., Feng, P., Zhang, X., et al.The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of strokeNeuropharmacology158:107748(2019)